Literature DB >> 19629792

Positive and negative symptoms in schizophrenia: the NMDA receptor hypofunction hypothesis, neuregulin/ErbB4 and synapse regression.

Maxwell Bennett1.   

Abstract

Carlsson has put forward the hypothesis that the positive and negative symptoms of schizophrenia are due to failure of mesolimbic and mesocortical projections consequent on hypofunction of the glutamate N-methyl-d-aspartate (NMDA) receptor. The hypothesis has been recently emphasized in this Journal that the loss of synaptic spines with NMDA receptors, which can be precipitated by stress, can explain the emergence of positive symptoms such as hallucinations and that this synapse regression involves molecules such as neuregulin and its receptor ErbB4 that have been implicated in schizophrenia. In this essay these two hypotheses are brought together in a single scheme in which emphasis is placed on the molecular pathways from neuregulin/ErbB4, to modulation of the NMDA receptors, subsequent changes in the synaptic spine's cytoskeletal apparatus and so regression of the spines. It is suggested that identification of the molecular constituents of this pathway will allow synthesis of suitable substances for removing the hypofunction of NMDA receptors and so the phenotypic consequences that flow from this hypofunction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19629792     DOI: 10.1080/00048670903001943

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  16 in total

1.  Loss of function studies in mice and genetic association link receptor protein tyrosine phosphatase α to schizophrenia.

Authors:  Nagahide Takahashi; Karin Sandager Nielsen; Branko Aleksic; Steffen Petersen; Masashi Ikeda; Itaru Kushima; Nathalie Vacaresse; Hiroshi Ujike; Nakao Iwata; Véronique Dubreuil; Naheed Mirza; Takeshi Sakurai; Norio Ozaki; Joseph D Buxbaum; Jan Sap
Journal:  Biol Psychiatry       Date:  2011-08-10       Impact factor: 13.382

2.  Evidence of altered polyamine concentrations in cerebral cortex of suicide completers.

Authors:  Gary Gang Chen; Laura M Fiori; Luc Moquin; Alain Gratton; Orval Mamer; Naguib Mechawar; Gustavo Turecki
Journal:  Neuropsychopharmacology       Date:  2010-03-03       Impact factor: 7.853

3.  Xanthoceraside prevented synaptic loss and reversed learning-memory deficits in APP/PS1 transgenic mice.

Authors:  Ge Jin; Lin Zhu; Peng Liu; Qian Xu; Yue Qi; Xiaoyu Zhou; Jikai Xu; Xuefei Ji; Tianyan Chi; Libo Zou
Journal:  J Physiol Sci       Date:  2019-02-14       Impact factor: 2.781

Review 4.  Neuregulin 1-erbB4 pathway in schizophrenia: From genes to an interactome.

Authors:  Anamika Banerjee; Mathew L Macdonald; Karin E Borgmann-Winter; Chang-Gyu Hahn
Journal:  Brain Res Bull       Date:  2010-04-28       Impact factor: 4.077

Review 5.  Glutamatergic autoencephalitides: an emerging field.

Authors:  Jessica A Panzer; Amy J Gleichman; David R Lynch
Journal:  J Neural Transm (Vienna)       Date:  2014-01-09       Impact factor: 3.575

6.  Efficacy of adjunctive D-Cycloserine for the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Pooja Patnaik Kuppili; Vikas Menon; Gopinath Sathyanarayanan; Siddharth Sarkar; Chittaranjan Andrade
Journal:  J Neural Transm (Vienna)       Date:  2021-01-13       Impact factor: 3.575

Review 7.  When cortical development goes wrong: schizophrenia as a neurodevelopmental disease of microcircuits.

Authors:  Laurence Garey
Journal:  J Anat       Date:  2010-10       Impact factor: 2.610

Review 8.  Genomics and pharmacogenomics of schizophrenia.

Authors:  Ramón Cacabelos; Rocío Martínez-Bouza
Journal:  CNS Neurosci Ther       Date:  2010-08-16       Impact factor: 5.243

9.  Reversible overexpression of bace1-cleaved neuregulin-1 N-terminal fragment induces schizophrenia-like phenotypes in mice.

Authors:  Xiaoyang Luo; Wanxia He; Xiangyou Hu; Riqiang Yan
Journal:  Biol Psychiatry       Date:  2013-10-05       Impact factor: 13.382

Review 10.  The involvement of N-methyl-D-aspartate receptor (NMDAR) subunit NR1 in the pathophysiology of schizophrenia.

Authors:  Peijun Ju; Donghong Cui
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2016-02-01       Impact factor: 3.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.